These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 30027336)

  • 1. Implementing Optimal Designs for Dose-Response Studies Through Adaptive Randomization for a Small Population Group.
    Ryeznik Y; Sverdlov O; Hooker AC
    AAPS J; 2018 Jul; 20(5):85. PubMed ID: 30027336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-stage response adaptive randomization designs for multi-arm trials with binary outcome.
    Lu X; Shan G
    J Biopharm Stat; 2024 Jul; 34(4):526-538. PubMed ID: 37452825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementing unequal randomization in clinical trials with heterogeneous treatment costs.
    Sverdlov O; Ryeznik Y
    Stat Med; 2019 Jul; 38(16):2905-2927. PubMed ID: 31049999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient and ethical response-adaptive randomization designs for multi-arm clinical trials with Weibull time-to-event outcomes.
    Sverdlov O; Ryeznik Y; Wong WK
    J Biopharm Stat; 2014; 24(4):732-54. PubMed ID: 24697678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simulation study for comparing testing statistics in response-adaptive randomization.
    Gu X; Lee JJ
    BMC Med Res Methodol; 2010 Jun; 10():48. PubMed ID: 20525382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical inference for response adaptive randomization procedures with adjusted optimal allocation proportions.
    Zhu H
    J Biopharm Stat; 2017; 27(5):732-740. PubMed ID: 27937121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of restricted randomization procedures for multiarm trials with equal or unequal treatment allocation ratios.
    Ryeznik Y; Sverdlov O
    Stat Med; 2018 Sep; 37(21):3056-3077. PubMed ID: 29869347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A group sequential, response-adaptive design for randomized clinical trials.
    Karrison TG; Huo D; Chappell R
    Control Clin Trials; 2003 Oct; 24(5):506-22. PubMed ID: 14500050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of methods for control allocation in multiple arm studies using response adaptive randomization.
    Viele K; Broglio K; McGlothlin A; Saville BR
    Clin Trials; 2020 Feb; 17(1):52-60. PubMed ID: 31630567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved adaptive randomization strategies for a seamless Phase I/II dose-finding design.
    Yan D; Wages NA; Dressler EV
    J Biopharm Stat; 2019; 29(2):333-347. PubMed ID: 30451068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical Considerations and Software for Designing Sequential, Multiple Assignment, Randomized Trials (SMART) with a Survival Final Endpoint.
    Kravets S; Ruppert AS; Jacobson SB; Le-Rademacher JG; Mandrekar SJ
    J Biopharm Stat; 2024 Jul; 34(4):539-552. PubMed ID: 37434437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal response-adaptive randomized designs for multi-armed survival trials.
    Sverdlov O; Tymofyeyev Y; Wong WK
    Stat Med; 2011 Oct; 30(24):2890-910. PubMed ID: 21823146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes.
    Ryeznik Y; Sverdlov O; Hooker AC
    AAPS J; 2017 Dec; 20(1):24. PubMed ID: 29285730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Balancing statistical and ethical considerations in planning clinical trials: recommendations for response-adaptive randomization urn designs.
    Piccorelli AV; Fraker SA
    J Biopharm Stat; 2018; 28(6):1105-1118. PubMed ID: 29442610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urn models for response-adaptive randomized designs: a simulation study based on a non-adaptive randomized trial.
    Ghiglietti A; Scarale MG; Miceli R; Ieva F; Mariani L; Gavazzi C; Paganoni AM; Edefonti V
    J Biopharm Stat; 2018; 28(6):1203-1215. PubMed ID: 29565749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials.
    Lin J; Bunn V
    Contemp Clin Trials; 2017 Mar; 54():48-59. PubMed ID: 28089763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of constrained randomization for the design and analysis of group-randomized trials with binary outcomes.
    Li F; Turner EL; Heagerty PJ; Murray DM; Vollmer WM; DeLong ER
    Stat Med; 2017 Oct; 36(24):3791-3806. PubMed ID: 28786223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
    Zhou X; Liu S; Kim ES; Herbst RS; Lee JJ
    Clin Trials; 2008; 5(3):181-93. PubMed ID: 18559407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A class of Covariate-Adjusted Response-Adaptive Allocation Designs for Multitreatment Binary Response Trials.
    Biswas A; Bhattacharya R
    J Biopharm Stat; 2018; 28(5):809-823. PubMed ID: 29913107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim analysis of binary outcome data in clinical trials: a comparison of five estimators.
    Lu QS; Chow SC; Tse SK
    J Biopharm Stat; 2019; 29(2):400-410. PubMed ID: 30599798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.